Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$0.87 USD
+0.04 (5.31%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $0.89 +0.02 (1.83%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Ovid Therapeutics (OVID) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.12 | $5.00 | $1.20 | 275.90% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Ovid Therapeutics comes to $3.12. The forecasts range from a low of $1.20 to a high of $5.00. The average price target represents an increase of 275.9% from the last closing price of $0.83.
Analyst Price Targets (6 )
Broker Rating
Ovid Therapeutics currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.22 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, seven are Strong Buy, representing 77.78% of all recommendations. A month ago, Strong Buy represented 88.89%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/OVID.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 8 | 8 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.44 | 1.44 | 1.22 | 1.22 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/18/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
6/18/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/18/2024 | Not Identified | Not Identified | Hold | Hold |
5/16/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
4/30/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Strong Buy |
4/5/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/1/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 9 |
Average Target Price | $3.12 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 68 of 252 |
Current Quarter EPS Est: | -0.22 |